vimarsana.com
Home
Live Updates
Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients : vimarsana.com
Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
- Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) -ROCKVILLE, Md., April 13, 2023 (GLOBE NEWSWIRE)
Related Keywords
Denmark ,
Copenhagen ,
Køavn ,
United States ,
American ,
Theriva Biologics ,
Erikr Dubberke ,
Chris Calabrese ,
Bella Centre Copenhagen ,
Theriva Biologics Inc ,
Safety Monitoring Committee ,
Washington University School Of Medicine ,
European Congress ,
Lifesci Advisors ,
Company Annual Report On Form ,
Clinical Microbiology ,
Infectious Diseases ,
Clinical Director ,
Transplant Infectious Diseases ,
Washington University School ,
Private Securities Litigation Reform Act ,
Annual Report ,
Sci Advisors ,
Theriva ,
Iologics ,
Nnounces ,
Presentation ,
Data ,
Rom ,
Cohort ,
Hase ,
Linical ,
Trial ,
Ibaxamase ,
Allogeneic ,
Ematopoietic ,
Fell ,
Transplant ,
Recipients ,
vimarsana.com © 2020. All Rights Reserved.